Low vitamin D levels may increase risk of urinary incontinence in pregnancy: Study

Written By :  Dr Satabdi Saha
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-11-13 07:15 GMT   |   Update On 2020-11-13 10:07 GMT

A recently published study in Obstetrics & Gynaecology, has suggested a significant association between low Serum 25(OH)D of less than 50 nmol/l with increased risk of any urinary incontinence (UI), among the pregnant women.Low levels of vitamin D are associated with increased risk of urinary incontinence in pregnancy.

The main function of the pelvic floor is to support pelvic organs and so maintain continence. Weakness of pelvic floor muscles is associated with urinary incontinence (UI), which is the most frequently reported symptoms. vitamin D has an essential role in regulation of calcium and bone homeostasis.Parathyroid hormone (PTH) interacts with vitamin D in this regulation, and serum levels of PTH reflect vitamin D status. During pregnancy, physiological changes such as increased intra‐abdominal pressure and pregnancy‐related hormonal changes may lead to reduced strength and reduced supportive and sphincter functions of the pelvic floor muscles.

Advertisement

Previously, numerous studies have found that vitamin D affects muscle strength and function, and low serum levels of vitamin D are associated with reduced muscle mass, strength and performance as well as increased risk of falls in the elderly.

Vitamin D status is assessed by measuring the level of circulating 25‐hydroxvitamin D (25(OH)D).Vitamin D insufficiency has emerged as a risk factor for PFDs. A positive correlation between antepartum vitamin D levels and postpartum pelvic floor muscle strength and endurance has been observed.

With this knowledge,Researchers undertook the study to assess the association between levels of vitamin D and urinary incontinence (UI) in pregnancy.

The study was designed as a cross‐sectional study. It was a Secondary analysis of a randomised controlled trial.

A total of 851 healthy, pregnant women >18 years in gestational weeks 18–22 with a singleton live fetus.Data on UI were collected from a questionnaire at inclusion and serum analysis of 25‐hydroxy vitamin D (25(OH)D) was performed. Univariable and multivariable logistic regression analyses were applied to study associations between exposure and outcomes.

Main outcome measures assessed was Prevalence of self‐reported UI, stress (SUI) and urge (UUI) or mixed UI.

On data analysis, the following facts emerged.

  • In total, 230/851 (27%) of the participants were vitamin D insufficient (25(OH)D <50 nmol/l) and 42% reported to have any UI.
  • Women with 25(OH)D <50 nmol/l were more likely to report any UI (P = 0.03) and SUI (P < 0.01) compared with women with 25(OH)D ≥50 nmol/l.
  • In a univariable logistic regression analysis, serum levels of 25(OH)D <50 nmol/l was associated with increased risk of any UI (odds ratio [OR] 1.5 with 95% CI 1.0–2.1), SUI only (OR 1.7, 95% CI 1.2–2.4), but not mixed UI or UUI only (OR 0.8, 95% CI 0.5–1.5).
  • In a multivariable logistic regression model, serum levels of 25(OH)D <50 nmol/l were associated with a higher risk of experiencing SUI only (OR 1.5, 95% CI 1.1–2.2).

Considering that serum 25(OH)D <50 nmol/l was associated with increased risk of any UI and SUI in the present study, our findings support the hypothesis that vitamin D plays a role in the function of the pelvic floor muscles during pregnancy. Whether vitamin D deficiency (25(OH)D <30 nmol/l) is associated with an even higher risk of UI could not be assessed because of the small number of women in this category."wrote the team.

For the full article follow the link: https://doi.org/10.1111/1471-0528.16398

Primary source: Obstetrics & Gynaecology

Tags:    
Article Source : Obstetrics & Gynaecology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News